🚀 VC round data is live in beta, check it out!
Vazyme Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vazyme Biotech and similar public comparables like Azenta, Suzhou Sepax Technologies, GemPharmatech, CareDx and more.
Vazyme Biotech Overview
About Vazyme Biotech
Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.
Founded
2012
HQ
Employees
N/A
Website
Financials (LTM)
EV
$928M
Vazyme Biotech Financials
Vazyme Biotech reported last 12-month revenue of $222M and EBITDA of $35M.
In the same LTM period, Vazyme Biotech generated $155M in gross profit, $35M in EBITDA, and $3M in net income.
Revenue (LTM)
Vazyme Biotech P&L
In the most recent fiscal year, Vazyme Biotech reported revenue of $200M and EBITDA of $18M.
Vazyme Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $222M | XXX | $200M | XXX | XXX | XXX |
| Gross Profit | $155M | XXX | $140M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $35M | XXX | $18M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 9% | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | (4%) | XXX | XXX | XXX |
| Net Profit | $3M | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | 1% | XXX | (1%) | XXX | XXX | XXX |
| Net Debt | — | — | $17M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vazyme Biotech Stock Performance
Vazyme Biotech has current market cap of $1B, and enterprise value of $928M.
Market Cap Evolution
Vazyme Biotech's stock price is $3.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $928M | $1B | 0.0% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVazyme Biotech Valuation Multiples
Vazyme Biotech trades at 4.2x EV/Revenue multiple, and 26.7x EV/EBITDA.
EV / Revenue (LTM)
Vazyme Biotech Financial Valuation Multiples
As of March 23, 2026, Vazyme Biotech has market cap of $1B and EV of $928M.
Equity research analysts estimate Vazyme Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vazyme Biotech has a P/E ratio of 430.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $928M | XXX | $928M | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | 26.7x | XXX | 50.9x | XXX | XXX | XXX |
| EV/EBIT | 280.0x | XXX | (115.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 6.0x | XXX | 6.6x | XXX | XXX | XXX |
| P/E | 430.6x | XXX | (487.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (75.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vazyme Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vazyme Biotech Margins & Growth Rates
Vazyme Biotech's revenue in the last 12 month grew by 25%.
Vazyme Biotech's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vazyme Biotech's rule of X is 77% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Vazyme Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 84% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 77% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 36% | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 15% | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 20% | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 74% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vazyme Biotech Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics and Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Azenta | XXX | XXX | XXX | XXX | XXX | XXX |
| Suzhou Sepax Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| GemPharmatech | XXX | XXX | XXX | XXX | XXX | XXX |
| CareDx | XXX | XXX | XXX | XXX | XXX | XXX |
| Novogene | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vazyme Biotech M&A Activity
Vazyme Biotech acquired XXX companies to date.
Last acquisition by Vazyme Biotech was on XXXXXXXX, XXXXX. Vazyme Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vazyme Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVazyme Biotech Investment Activity
Vazyme Biotech invested in XXX companies to date.
Vazyme Biotech made its latest investment on XXXXXXXX, XXXXX. Vazyme Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vazyme Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vazyme Biotech
| When was Vazyme Biotech founded? | Vazyme Biotech was founded in 2012. |
| Where is Vazyme Biotech headquartered? | Vazyme Biotech is headquartered in China. |
| Is Vazyme Biotech publicly listed? | Yes, Vazyme Biotech is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Vazyme Biotech? | Vazyme Biotech trades under 688105 ticker. |
| When did Vazyme Biotech go public? | Vazyme Biotech went public in 2021. |
| Who are competitors of Vazyme Biotech? | Vazyme Biotech main competitors are Azenta, Suzhou Sepax Technologies, GemPharmatech, CareDx. |
| What is the current market cap of Vazyme Biotech? | Vazyme Biotech's current market cap is $1B. |
| What is the current revenue of Vazyme Biotech? | Vazyme Biotech's last 12 months revenue is $222M. |
| What is the current revenue growth of Vazyme Biotech? | Vazyme Biotech revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of Vazyme Biotech? | Current revenue multiple of Vazyme Biotech is 4.2x. |
| Is Vazyme Biotech profitable? | Yes, Vazyme Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vazyme Biotech? | Vazyme Biotech's last 12 months EBITDA is $35M. |
| What is Vazyme Biotech's EBITDA margin? | Vazyme Biotech's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Vazyme Biotech? | Current EBITDA multiple of Vazyme Biotech is 26.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.